Announcements Trials
Browse Landscape

Phase

Phase NA 16Phase 4 3Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 5Breast 5Thoracic 3Other hematologic neoplasm 3Genitourinary 3CNS 3Tumor-Agnostic 2Sarcoma 2Plasma cell 2Lymphoid 2Gynecologic 2Dermatologic 2Myeloid 1Endocrine 1

Conditions

Melanoma 2

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19HhAntag691 19Mycophenolic Acid 18Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Blood Specimen Collection × Dermatologic × Clear all
NCT02977052 2023-11-15

OpACIN-neo

The Netherlands Cancer Institute

Phase 2 Unknown
186 enrolled
Dermatologic

Melanoma

NCT02414750 2022-11-30

REPOSIT

Netherlands Working Group on Immunotherapy of Oncology

Phase 2 Terminated
78 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡